Dr Siddarth Sridhar from the Department of Microbiology at HKUMed discusses the status of Hydroxychloroquine for COVID-19. He mentions that initial excitement was generated in March due to evidence of the drug's effectiveness in vitro. However, subsequent studies have produced contradictory results, with some suggesting it may help reduce symptoms, while others find no difference in mortality rates or ICU transfers. Dr Sridhar emphasizes the need for a randomized control trial to definitively answer the question of Hydroxychloroquine's effectiveness.